Phase II Clinical Trial for Newly Diagnosed Children and Adolescents with Localized Lymphoblastic Lymphoma (Japanese Leukemia/Lymphoma Study Group Trial LLB-NHL03) : Study Protocol for Nationwide Multicenter Trial.
Phase II Clinical Trial for Newly Diagnosed Children and Adolescents with Localized Lymphoblastic Lymphoma (Japanese Leukemia/Lymphoma Study Group Trial LLB-NHL03) : Study Protocol for Nationwide Multicenter Trial.
Acta Med Okayama. 2018 Aug;72(4):427-430
Authors: Sekimizu M, Fujimoto J, Takimoto T, Tsurusawa M, Horibe K, Sunami S
Abstract
Pediatric patients with lymphoblastic lymphoma are generally treated using the Berlin-Frankfurt-Munster (BFM) 90 protocol, which is the standard treatment strategy for pediatric acute lymphoblastic leukemia, and have a favorable outcome. However, this intense regimen includes high total doses of anthracycline and alkylating agents, and is known to cause late complications. We therefore planned a clinical trial to examine the efficacy and safety of a modified BFM regimen. We expect that this phase II, nationwide multicenter trial will help to establish an effective and safer standard therapy for stage I/II pediatric lymphoblastic lymphoma.
PMID: 30140093 [PubMed - in process]
Source: Acta Medica Okayama - Category: General Medicine Tags: Acta Med Okayama Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Children | Clinical Trials | General Medicine | Japan Health | Leukemia | Lymphoma | Pediatrics | Study